| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Craniotomy | 3 | 2020 | 33 | 1.690 |
Why?
|
| Brain Neoplasms | 8 | 2020 | 371 | 1.310 |
Why?
|
| Pituitary Neoplasms | 4 | 2020 | 52 | 1.090 |
Why?
|
| Solitary Fibrous Tumors | 2 | 2022 | 4 | 0.950 |
Why?
|
| Glioblastoma | 8 | 2020 | 219 | 0.910 |
Why?
|
| Meningioma | 4 | 2020 | 54 | 0.630 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2020 | 444 | 0.600 |
Why?
|
| Histiocytoma, Malignant Fibrous | 1 | 2016 | 6 | 0.570 |
Why?
|
| Endoscopy | 5 | 2016 | 464 | 0.460 |
Why?
|
| Epilepsy, Temporal Lobe | 3 | 2021 | 138 | 0.440 |
Why?
|
| Sphenoid Bone | 1 | 2012 | 4 | 0.410 |
Why?
|
| Third Ventricle | 1 | 2012 | 4 | 0.410 |
Why?
|
| Hypothalamus | 1 | 2012 | 78 | 0.400 |
Why?
|
| Tumor Suppressor Proteins | 4 | 2020 | 194 | 0.390 |
Why?
|
| Meningeal Neoplasms | 2 | 2020 | 42 | 0.340 |
Why?
|
| Craniopharyngioma | 2 | 2020 | 7 | 0.330 |
Why?
|
| Electroencephalography | 4 | 2021 | 418 | 0.320 |
Why?
|
| Connectome | 2 | 2020 | 91 | 0.310 |
Why?
|
| Postoperative Complications | 5 | 2016 | 1615 | 0.310 |
Why?
|
| Epilepsy | 3 | 2022 | 336 | 0.310 |
Why?
|
| Lanosterol | 2 | 2019 | 11 | 0.300 |
Why?
|
| Heptanoic Acids | 2 | 2019 | 28 | 0.300 |
Why?
|
| Allyl Compounds | 3 | 2018 | 29 | 0.300 |
Why?
|
| Sulfides | 3 | 2018 | 43 | 0.290 |
Why?
|
| Triterpenes | 2 | 2019 | 40 | 0.290 |
Why?
|
| Cerebrospinal Fluid Rhinorrhea | 3 | 2011 | 41 | 0.280 |
Why?
|
| Immunotoxins | 1 | 2006 | 23 | 0.270 |
Why?
|
| Radioisotopes | 1 | 2006 | 40 | 0.270 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2018 | 116 | 0.260 |
Why?
|
| DNA Modification Methylases | 3 | 2020 | 24 | 0.260 |
Why?
|
| Histone Deacetylases | 2 | 2018 | 99 | 0.250 |
Why?
|
| DNA Repair Enzymes | 3 | 2020 | 53 | 0.250 |
Why?
|
| Glioma | 1 | 2006 | 140 | 0.250 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2021 | 2222 | 0.250 |
Why?
|
| Skull Base | 3 | 2016 | 72 | 0.250 |
Why?
|
| Humans | 34 | 2022 | 68549 | 0.240 |
Why?
|
| Adenoma | 2 | 2015 | 132 | 0.230 |
Why?
|
| Drug Resistant Epilepsy | 2 | 2021 | 44 | 0.230 |
Why?
|
| Cyclin-Dependent Kinase 6 | 2 | 2020 | 28 | 0.230 |
Why?
|
| Cyclin-Dependent Kinase 4 | 2 | 2020 | 35 | 0.230 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2020 | 57 | 0.230 |
Why?
|
| Electrodes, Implanted | 2 | 2021 | 98 | 0.220 |
Why?
|
| Benzimidazoles | 2 | 2020 | 128 | 0.210 |
Why?
|
| Vagus Nerve Stimulation | 1 | 2022 | 61 | 0.200 |
Why?
|
| Cerebrospinal Fluid Leak | 3 | 2016 | 32 | 0.200 |
Why?
|
| Apoptosis | 6 | 2020 | 1641 | 0.190 |
Why?
|
| Neurofibromin 2 | 1 | 2020 | 10 | 0.180 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2020 | 14 | 0.180 |
Why?
|
| Quinolones | 1 | 2020 | 60 | 0.170 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2020 | 79 | 0.170 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 100 | 0.170 |
Why?
|
| Neurosurgical Procedures | 1 | 2020 | 98 | 0.170 |
Why?
|
| Phosphatidylinositol 3-Kinases | 4 | 2020 | 223 | 0.170 |
Why?
|
| Brain | 2 | 2021 | 2176 | 0.170 |
Why?
|
| Cell Line, Tumor | 6 | 2020 | 1851 | 0.170 |
Why?
|
| Adult | 12 | 2021 | 21379 | 0.170 |
Why?
|
| Machine Learning | 1 | 2020 | 170 | 0.160 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2020 | 332 | 0.160 |
Why?
|
| Seizures | 1 | 2021 | 279 | 0.160 |
Why?
|
| Piperazines | 1 | 2020 | 206 | 0.160 |
Why?
|
| Stroke Rehabilitation | 1 | 2022 | 335 | 0.160 |
Why?
|
| White Matter | 1 | 2021 | 174 | 0.160 |
Why?
|
| Pyridines | 1 | 2020 | 261 | 0.160 |
Why?
|
| Treatment Outcome | 8 | 2022 | 7028 | 0.150 |
Why?
|
| Female | 15 | 2021 | 38021 | 0.140 |
Why?
|
| Syndecan-1 | 1 | 2016 | 4 | 0.140 |
Why?
|
| Cranial Fossa, Middle | 1 | 2016 | 8 | 0.140 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2016 | 30 | 0.140 |
Why?
|
| Male | 17 | 2021 | 37283 | 0.140 |
Why?
|
| Combined Modality Therapy | 4 | 2020 | 951 | 0.140 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2019 | 304 | 0.140 |
Why?
|
| Encephalocele | 2 | 2016 | 30 | 0.130 |
Why?
|
| Middle Aged | 14 | 2021 | 21119 | 0.130 |
Why?
|
| Gamma Rays | 1 | 2015 | 64 | 0.130 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2015 | 30 | 0.130 |
Why?
|
| Intraoperative Complications | 1 | 2016 | 129 | 0.130 |
Why?
|
| Speech | 1 | 2017 | 118 | 0.130 |
Why?
|
| Esthesioneuroblastoma, Olfactory | 1 | 2015 | 10 | 0.130 |
Why?
|
| Antigens, CD | 1 | 2016 | 230 | 0.130 |
Why?
|
| Temporal Lobe | 1 | 2016 | 125 | 0.130 |
Why?
|
| Natural Orifice Endoscopic Surgery | 1 | 2015 | 24 | 0.130 |
Why?
|
| Nose Neoplasms | 1 | 2015 | 25 | 0.130 |
Why?
|
| Limonins | 1 | 2015 | 10 | 0.130 |
Why?
|
| Catechols | 1 | 2015 | 14 | 0.130 |
Why?
|
| Flavones | 1 | 2015 | 11 | 0.130 |
Why?
|
| Receptors, Cell Surface | 1 | 2016 | 248 | 0.130 |
Why?
|
| Fatty Alcohols | 1 | 2015 | 14 | 0.130 |
Why?
|
| Sesquiterpenes | 1 | 2015 | 41 | 0.130 |
Why?
|
| SEER Program | 1 | 2015 | 150 | 0.130 |
Why?
|
| Necrosis | 1 | 2015 | 239 | 0.130 |
Why?
|
| Radiation Injuries | 1 | 2015 | 97 | 0.130 |
Why?
|
| Nasal Cavity | 1 | 2015 | 62 | 0.130 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2014 | 16 | 0.120 |
Why?
|
| Hypophysectomy | 1 | 2014 | 5 | 0.120 |
Why?
|
| Operative Time | 1 | 2014 | 45 | 0.120 |
Why?
|
| Hydrocephalus | 1 | 2014 | 40 | 0.120 |
Why?
|
| Microsurgery | 1 | 2014 | 46 | 0.120 |
Why?
|
| Brain Mapping | 1 | 2017 | 531 | 0.120 |
Why?
|
| Cerebral Cortex | 1 | 2017 | 415 | 0.120 |
Why?
|
| Epigenesis, Genetic | 1 | 2015 | 163 | 0.110 |
Why?
|
| Spinal Neoplasms | 1 | 2013 | 14 | 0.110 |
Why?
|
| Vertebroplasty | 1 | 2013 | 16 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2013 | 33 | 0.110 |
Why?
|
| Bone Cements | 1 | 2013 | 39 | 0.110 |
Why?
|
| Thoracic Vertebrae | 1 | 2013 | 52 | 0.110 |
Why?
|
| Mice, SCID | 3 | 2019 | 238 | 0.110 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2013 | 100 | 0.110 |
Why?
|
| Hemangioma | 1 | 2013 | 51 | 0.110 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 1070 | 0.100 |
Why?
|
| Hypothalamic Neoplasms | 1 | 2012 | 2 | 0.100 |
Why?
|
| Cerebral Ventricle Neoplasms | 1 | 2012 | 3 | 0.100 |
Why?
|
| Retrospective Studies | 7 | 2021 | 7268 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2020 | 331 | 0.100 |
Why?
|
| Aged | 9 | 2021 | 14842 | 0.100 |
Why?
|
| Empty Sella Syndrome | 1 | 2011 | 10 | 0.100 |
Why?
|
| Meningocele | 1 | 2011 | 12 | 0.100 |
Why?
|
| Fistula | 1 | 2011 | 29 | 0.100 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2012 | 85 | 0.100 |
Why?
|
| Skull Base Neoplasms | 1 | 2011 | 13 | 0.100 |
Why?
|
| Mucocele | 1 | 2011 | 20 | 0.100 |
Why?
|
| Pseudotumor Cerebri | 1 | 2011 | 43 | 0.100 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2011 | 24 | 0.090 |
Why?
|
| Spinal Cord Compression | 1 | 2011 | 23 | 0.090 |
Why?
|
| Embolization, Therapeutic | 1 | 2013 | 150 | 0.090 |
Why?
|
| Transferrin | 1 | 2011 | 94 | 0.090 |
Why?
|
| Surgical Flaps | 1 | 2011 | 120 | 0.090 |
Why?
|
| Cell Proliferation | 3 | 2020 | 1174 | 0.090 |
Why?
|
| bcl-2-Associated X Protein | 2 | 2020 | 111 | 0.090 |
Why?
|
| Stroke | 1 | 2022 | 2162 | 0.090 |
Why?
|
| Young Adult | 5 | 2021 | 5710 | 0.080 |
Why?
|
| Risk Assessment | 1 | 2015 | 2004 | 0.080 |
Why?
|
| Diffusion Tensor Imaging | 2 | 2021 | 211 | 0.080 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2011 | 163 | 0.080 |
Why?
|
| Astrocytes | 2 | 2020 | 270 | 0.070 |
Why?
|
| Liver Neoplasms | 1 | 2011 | 334 | 0.070 |
Why?
|
| Benzamides | 2 | 2020 | 156 | 0.070 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2020 | 71 | 0.070 |
Why?
|
| Ethanol | 1 | 2013 | 892 | 0.070 |
Why?
|
| Infusion Pumps | 1 | 2006 | 39 | 0.070 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2020 | 689 | 0.070 |
Why?
|
| Neoplasm Staging | 2 | 2020 | 799 | 0.070 |
Why?
|
| Blood-Brain Barrier | 1 | 2006 | 99 | 0.070 |
Why?
|
| Animals | 6 | 2020 | 20880 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2020 | 331 | 0.060 |
Why?
|
| Reoperation | 2 | 2016 | 467 | 0.060 |
Why?
|
| Drug Delivery Systems | 1 | 2006 | 236 | 0.060 |
Why?
|
| Neurons | 2 | 2020 | 881 | 0.060 |
Why?
|
| Patient Readmission | 2 | 2016 | 267 | 0.060 |
Why?
|
| Signal Transduction | 3 | 2020 | 2689 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2020 | 756 | 0.050 |
Why?
|
| Length of Stay | 2 | 2016 | 780 | 0.050 |
Why?
|
| Vagus Nerve | 1 | 2022 | 90 | 0.050 |
Why?
|
| Child, Preschool | 2 | 2021 | 3187 | 0.050 |
Why?
|
| Mice | 3 | 2020 | 8474 | 0.050 |
Why?
|
| Corpus Callosum | 1 | 2021 | 29 | 0.050 |
Why?
|
| Adolescent | 3 | 2021 | 8904 | 0.050 |
Why?
|
| Parahippocampal Gyrus | 1 | 2020 | 15 | 0.050 |
Why?
|
| G1 Phase Cell Cycle Checkpoints | 1 | 2020 | 12 | 0.050 |
Why?
|
| Cyclin D | 1 | 2020 | 12 | 0.050 |
Why?
|
| Smad Proteins | 1 | 2020 | 25 | 0.050 |
Why?
|
| Guanine | 1 | 2020 | 21 | 0.050 |
Why?
|
| Sulfones | 1 | 2020 | 45 | 0.050 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2020 | 22 | 0.050 |
Why?
|
| Aminopyridines | 1 | 2020 | 26 | 0.050 |
Why?
|
| bcl-X Protein | 1 | 2020 | 36 | 0.050 |
Why?
|
| Quinolines | 1 | 2020 | 48 | 0.050 |
Why?
|
| Triazines | 1 | 2020 | 48 | 0.040 |
Why?
|
| Gray Matter | 1 | 2020 | 57 | 0.040 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2022 | 373 | 0.040 |
Why?
|
| Wnt2 Protein | 1 | 2019 | 4 | 0.040 |
Why?
|
| Anaplasia | 1 | 2019 | 7 | 0.040 |
Why?
|
| Azacitidine | 1 | 2019 | 20 | 0.040 |
Why?
|
| Retinoblastoma Protein | 1 | 2020 | 75 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2022 | 356 | 0.040 |
Why?
|
| Imidazoles | 1 | 2020 | 175 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 110 | 0.040 |
Why?
|
| Caspase 3 | 1 | 2020 | 233 | 0.040 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2019 | 77 | 0.040 |
Why?
|
| ROC Curve | 1 | 2020 | 392 | 0.040 |
Why?
|
| Incidence | 2 | 2015 | 1582 | 0.040 |
Why?
|
| Fibrinolytic Agents | 1 | 2022 | 377 | 0.040 |
Why?
|
| Pyrimidines | 1 | 2020 | 178 | 0.040 |
Why?
|
| Pyrazoles | 1 | 2020 | 190 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2019 | 196 | 0.040 |
Why?
|
| Cell Cycle | 1 | 2020 | 312 | 0.040 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2019 | 118 | 0.040 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2019 | 160 | 0.040 |
Why?
|
| Cell Death | 1 | 2019 | 329 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 170 | 0.040 |
Why?
|
| In Vitro Techniques | 1 | 2019 | 765 | 0.040 |
Why?
|
| Nerve Net | 1 | 2020 | 180 | 0.040 |
Why?
|
| DNA Methylation | 1 | 2019 | 193 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2019 | 447 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2022 | 2324 | 0.040 |
Why?
|
| Child | 2 | 2021 | 6401 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 2011 | 1140 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 1 | 2019 | 614 | 0.040 |
Why?
|
| Cell Survival | 1 | 2020 | 901 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 467 | 0.040 |
Why?
|
| Sample Size | 1 | 2017 | 79 | 0.040 |
Why?
|
| Chordoma | 1 | 2016 | 9 | 0.040 |
Why?
|
| Pneumocephalus | 1 | 2016 | 12 | 0.040 |
Why?
|
| Phosphorylation | 1 | 2019 | 1200 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2016 | 4843 | 0.030 |
Why?
|
| Neural Pathways | 1 | 2018 | 323 | 0.030 |
Why?
|
| Auditory Perception | 1 | 2017 | 89 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2015 | 196 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2015 | 50 | 0.030 |
Why?
|
| Caspases | 1 | 2015 | 194 | 0.030 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2015 | 57 | 0.030 |
Why?
|
| DNA Fragmentation | 1 | 2015 | 85 | 0.030 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2015 | 64 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2020 | 2673 | 0.030 |
Why?
|
| Mutation | 1 | 2020 | 1213 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2015 | 272 | 0.030 |
Why?
|
| Wnt Signaling Pathway | 1 | 2015 | 57 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 1745 | 0.030 |
Why?
|
| Hydroxamic Acids | 1 | 2015 | 84 | 0.030 |
Why?
|
| Catheters | 1 | 2014 | 39 | 0.030 |
Why?
|
| Decision Trees | 1 | 2014 | 74 | 0.030 |
Why?
|
| Oligopeptides | 1 | 2015 | 152 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2015 | 852 | 0.030 |
Why?
|
| Models, Economic | 1 | 2014 | 69 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2016 | 880 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2014 | 105 | 0.030 |
Why?
|
| Fatty Acids | 1 | 2015 | 222 | 0.030 |
Why?
|
| Markov Chains | 1 | 2014 | 133 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2015 | 954 | 0.030 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2013 | 160 | 0.030 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2013 | 100 | 0.030 |
Why?
|
| Survival Rate | 1 | 2015 | 1055 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2014 | 307 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2014 | 503 | 0.030 |
Why?
|
| Garlic | 1 | 2012 | 12 | 0.030 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2012 | 37 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2015 | 508 | 0.030 |
Why?
|
| Sex Factors | 1 | 2015 | 1265 | 0.020 |
Why?
|
| Cerebrospinal Fluid Pressure | 1 | 2011 | 13 | 0.020 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2012 | 64 | 0.020 |
Why?
|
| Standard of Care | 1 | 2011 | 22 | 0.020 |
Why?
|
| Logistic Models | 1 | 2015 | 1419 | 0.020 |
Why?
|
| Flavonoids | 1 | 2012 | 109 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2012 | 174 | 0.020 |
Why?
|
| Mucous Membrane | 1 | 2011 | 66 | 0.020 |
Why?
|
| Neoplastic Stem Cells | 1 | 2012 | 84 | 0.020 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2012 | 120 | 0.020 |
Why?
|
| Laminectomy | 1 | 2011 | 13 | 0.020 |
Why?
|
| DNA Repair | 1 | 2012 | 127 | 0.020 |
Why?
|
| Spinal Puncture | 1 | 2011 | 38 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2015 | 2083 | 0.020 |
Why?
|
| Head and Neck Neoplasms | 1 | 2016 | 561 | 0.020 |
Why?
|
| Retinoids | 1 | 2012 | 122 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2013 | 1040 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2011 | 164 | 0.020 |
Why?
|
| Electrophoresis | 1 | 2011 | 69 | 0.020 |
Why?
|
| Prognosis | 1 | 2015 | 2093 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2012 | 434 | 0.020 |
Why?
|
| Infant | 1 | 2016 | 2891 | 0.020 |
Why?
|
| Disease Progression | 1 | 2013 | 1037 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2011 | 201 | 0.020 |
Why?
|
| Liver | 1 | 2013 | 1118 | 0.020 |
Why?
|
| Rats | 1 | 2015 | 5300 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 848 | 0.020 |
Why?
|
| MicroRNAs | 1 | 2012 | 447 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 1753 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2013 | 2550 | 0.020 |
Why?
|
| Risk Factors | 1 | 2015 | 5720 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 3256 | 0.020 |
Why?
|
| United States | 1 | 2015 | 7338 | 0.010 |
Why?
|